{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:04:03Z","timestamp":1793189043386,"version":"4.5.0"},"reference-count":21,"publisher":"Centers for Disease Control MMWR Office","issue":"46","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm6846a4","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T10:58:55Z","timestamp":1574333935000},"page":"1062-1068","source":"Crossref","is-referenced-by-count":48,"title":["Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria \u2014 United States, 2019"],"prefix":"10.15585","volume":"68","author":[{"given":"Julia C.","family":"Haston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R1","unstructured":"World Health Organization. World malaria report 2018. Geneva, Switzerland: World Health Organization; 2018. https:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/en\/"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R2","unstructured":"CDC. Yellow book 2018: health information for international travel. New York, NY: Oxford University Press; 2017."},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R3","unstructured":"Food and Drug Administration. Krintafel (tafenoquine) tablets. GlaxoSmithKline. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210795Orig1s000TOC.cfm"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R4","unstructured":"Food and Drug Administration. Arakoda (tafenoquine) tablets. Sixty Degrees Pharmaceuticals, LLC. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210607Orig1s000TOC.cfm"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R5","doi-asserted-by":"crossref","unstructured":"Mace KE, Arguin PM, Lucchi NW, Tan KR. Malaria surveillance\u2014United States, 2016. MMWR Surveill Summ 2019;68(No. SS-5).","DOI":"10.15585\/mmwr.ss6805a1"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4269\/ajtmh.2006.75.402","article-title":"Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.","volume":"75","author":"Hill","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R7","unstructured":"Food and Drug Administration. Arakoda (tafenoquine) tablets. Sixty Degrees Pharmaceuticals, LLC. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210607lbl.pdf"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R8","unstructured":"Food and Drug Administration. Krintafel (tafenoquine) tablets. GlaxoSmithKline. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210795s000lbl.pdf"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.4269\/ajtmh.16-0779","article-title":"Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol Variant) versus G6PD-normal volunteers.","volume":"97","author":"Rueangweerayut","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R10","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay110","article-title":"Tafenoquine for travelers\u2019 malaria: evidence, rationale and recommendations.","volume":"25","author":"Baird","year":"2018","journal-title":"J Travel Med"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R11","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1086\/324081","article-title":"A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.","volume":"33","author":"Shanks","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1086\/367542","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.","volume":"36","author":"Hale","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1475-2875-13-49","article-title":"A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area.","volume":"13","author":"Dow","year":"2014","journal-title":"Malar J"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/cid\/ciy939","article-title":"Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blinded, placebo-controlled Phase 1b study.","volume":"69","author":"McCarthy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R16","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","article-title":"Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.","volume":"383","author":"Llanos-Cuentas","year":"2014","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","article-title":"Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria.","volume":"380","author":"Llanos-Cuentas","year":"2019","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","article-title":"Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria (DETECTIVE Phase III).","volume":"380","author":"Lacerda","year":"2019","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.pt.2007.04.009","article-title":"Plasmodium malariae and Plasmodium ovale\u2014the \u201cbashful\u201d malaria parasites.","volume":"23","author":"Mueller","year":"2007","journal-title":"Trends Parasitol"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.tmaid.2014.11.005","article-title":"Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers\u2014a retrospective analysis.","volume":"13","author":"Shimizu","year":"2015","journal-title":"Travel Med Infect Dis"},{"key":"key-10.15585\/mmwr.mm6846a4-201911211058-R21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jtm.12009","article-title":"Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008\u20132010).","volume":"20","author":"Faucher","year":"2013","journal-title":"J Travel Med"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T10:59:03Z","timestamp":1574333943000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/68\/wr\/mm6846a4.htm?s_cid=mm6846a4_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":21,"journal-issue":{"issue":"46","published-online":{"date-parts":[[2019,11,22]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm6846a4","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,22]]},"published":{"date-parts":[[2019,11,22]]}}}